Results 71 to 80 of about 32,623 (326)
British Journal of Clinical Pharmacology, EarlyView.Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun +4 more
wiley +1 more source
Lost and found in translation: the value of the human imiquimod model
British Journal of Clinical Pharmacology, EarlyView.Topical imiquimod (IMQ), a Toll‐like receptor (TLR) 7 agonist, induces transient cutaneous inflammation and is widely used in preclinical research as a ‘psoriasis‐like’ mouse model. However, accumulating evidence indicates substantial divergence between IMQ‐driven biology and human plaque psoriasis pathogenesis.
Anouk C. Meijs +6 more
wiley +1 more source
, 2013 Cutaneous manifestations occur frequently in systemic lupus erythematosus (SLE) and are pathognomonic in subacute-cutaneous lupus erythematosus (SCLE) and chronic cutaneous lupus erythematosus (CCLE).
Morris, SD +3 more
core
JPGN Reports, EarlyView.Abstract Wilson disease (WD) is an autosomal recessive disorder of hepatic copper metabolism with varied clinical presentations. We describe a 15‐year‐old male referred for elevated aminotransferases, burning facial pruritis, scalp dysesthesias, and chronic bilateral lower extremity edema.
Tierra L. R. Mosher +2 more
wiley +1 more source
Lupus profundus limited to a site of trauma: Case report and review of the literature
International Journal of Women's Dermatology, 2017 Lupus erythematosus profundus (LEP) is a rare form of chronic cutaneous lupus erythematosus. We report on a case of a 56-year-old Caucasian woman who presented with a single, persistent, painful rash on the left hip and lateral aspect of the left upper ...
María Adriana Castrillón, MD +1 more
doaj +1 more source
A review of the evidence and cost of therapies for cutaneous lupus erythematosus
, 2019 Cutaneous lupus erythematosus (CLE)—a common presentation of lupus erythematosus—may exist independently or as a part of the systemic manifestations of systemic lupus erythematosus.
Rosen, J D, Maderal, A, Paul, S
core +1 more source
Recalcitrant Eyelid Lupus Treated With Topical Ruxolitinib
JEADV Clinical Practice, EarlyView.ABSTRACT Lupus of the eyelids, or lupus blepharitis, is a rare and localized form of chronic cutaneous lupus. The use of topical corticosteroids is limited in this sensitive area due to the risk of adverse events. We present a case of eyelid lupus, with histological confirmation, resistant to multiple lines of treatment, successfully treated with ...
Clémence Bertold +6 more
wiley +1 more source
Anais Brasileiros de Dermatologia, 2012 Neonatal lupus erythematosus is an autoimmune disease produced by the passage of maternal antinuclear antibodies and extractable nuclear antigen antibodies through the placenta. At the moment of the diagnosis, the mothers are asymptomatic in 40 to 60% of
Marcos Noronha Frey +4 more
doaj +1 more source
Methotrexate therapy in systemic lupus erythematosus
, 2001 There are 12 non-controlled and only two controlled studies using methotrexate (MTX) in a total of 207 SLE patients in the literature. the majority of these studies evaluated mainly cutaneous and/or articular involvement and attained good results.
Sato, E. I.
core +1 more source
Apoptosis in chronic cutaneous lupus erythematosus, discoid lupus, and lupus profundus [PDF]
, 2015 : Introduction: Lupus erythematosus is a multisystemic disease that is characterized by autoantibody production and immune complex deposition in such tissues as the mucosa, joints, the central nervous system, and skin.
Felipe de Jesús, Torres del Muro +7 more
core +1 more source